## **FACULTY OF EXPERTS**

Expert	Country
Angela Lamarca	Spain
Chiara Cremolini	Italy
Cindy Neuzillet	France
Davide Melisi	Italy
Diogo Bugano	Brazil
Dominik Modest	Germany
Eric Van Cutsem	Belgium
Gerald Prager	Austria
Hossein Taghizadeh	Austria
Jenny Seligmann	UK
Julien Taieb	France
Mar Iglesias (pathologist)	Spain
Mohamed Abdullah	Egypt
Pascal Hammel	France
Surgeon (TBC)	Germany
Teresa Macarulla	Spain
Yannick Buccella	Switzerland

# GIC MASTERCLASS PROGRAM FIRST PROPOSAL

DAY 1: Thursday September 18 <sup>th</sup>			
14h00 – 16h30	Speakers' meeting		
17h00 – 17h30	Welcome Coffee		
17h30 – 17h50	Introduction	Lene Monica Mirella Sunny	
17h50 – 18h50	Introduction theme	TBC	
19h30 / 20h00	Dinner		

DAY 2: Friday September 19 <sup>th</sup>				
9h00 – 10h00	CRC Plenary	Chairs		
		J. Taieb + C. Cremolini		
		Speakers		
		C. Cremolini	Intro (5')	
		J. Seligmann	Current state of the art in mCRC management (25')	

		All	Discussion (5')	
		D. Modest	New insights and latest data: which opportunities for mCRC patients? (20')	
	-	J. Taieb	Conclusion (5')	
10h00 – 10h50	Workshop 1	Choice between pa	arallel workshops	
10h50 – 11h20	Coffee Break			
11h20 – 12h10	Workshop 2	Choice between parallel workshops		
12h10 – 13h30	Lunch			
13h30 – 14h30	CCA Plenary	Chairs		
		Surgeon + T. Macarulla		
		Speakers		
		A. Lamarca	A multidisciplinary approach starts from diagnosis (15')	
		M. Iglesias	Molecular testing in cholangiocarcinoma: are we there yet? (15')	
		C. Neuzillet	Cholangiocarcinoma in the Era of Targeted Therapies (15')	
		Q&A	15'	
14h30 – 15h20	Workshop 3	Choice between parallel workshops		
15h20 – 15h45	Coffee Break			
15h45 – 16h35	Workshop 4	Choice between parallel workshops		
16h45 – 17h35	Workshop 5	Choice between parallel workshops		
19h30	Departure from the hotel to the dinner			

DAY 3: Saturday September 20 <sup>th</sup>				
8h30 – 9h30	PAC plenary	E. Van Cutsem + P. Hammel		
		Speakers		
		E. Van Cutsem	Introduction (5')	
		T. Macarulla	Treatment landscape in locally and locally advanced PAC (15')	

		G. Prager	Evolving treatment in metastatic pancreatic cancer (20')
		D. Melisi	Future perspectives (15')
		P. Hammel	Conclusion (5')
9h30 – 10h15	Beyond Treatment	Chairs	
	plenary	Cremolini + Taieb	
		Speakers	
		C. Neuzillet	Supportive Care + adaptive physical activity
		D. Melisi	Pain management
10h15 – 10h40	Coffee Break		
10h40 – 11h30	Workshop 6	Choice between parallel workshops	
11h40 – 12h30	Workshop 7	Choice between parallel workshops	
12h30 – 12h40	Closing Plenary	Lene	
12h40	Lunch		•

### 7 WORKSHOPS SLOTS – 15 WORKSHOPS

## mPAC Workshops: (5)

• Pros&Cons: FOLFIRINOX vs NALIRIFOX

Gerald Prager – Pascal Hammel (FOLFIRINOX)

• Patients Cases in mPAC

Teresa Macarulla (LT survivors) – Mohamed Abdulla

• Targets in PAC: is it a reality in clinical practice?

Davide Melisi – Eric Van Cutsem

• Patient support beyond treatment in mPAC

Cindy Neuzillet – Angela Lamarca

• What to expect from real world evidence?

Hossein Taghizadeh – Yannick Buccella

## mCRC Workshops: (5)

• Patient Cases in mCRC: Inputs from clinical practice
Jenny Seligmann - Diogo Bugano

 Towards optimal sequencing in the light of ESMO guidelines: Focus on 3L and beyond

Julien Taieb – Dominik Modest

- Molecular profiling in mCRC: Where do we stand (KRAS/HER2/Codon12...)

  Dominik Modest Chiara Cremolini
- Patient management: maintaining QoL and tackling adverse events in later lines

Julien Taieb – Jenny Seligmann

• From diagnosis to later lines: Navigating through the continuum of care.

Eric Van Cutsem – Gerald Prager

## CCA Workshops: (5)

- Molecular profiling: Shaping the Future of Personalized Medicine
   Cindy Neuzillet + Mar Iglesias
- The Role of Multidisciplinary Teams (MDTs) in Improving Patients' Outcomes Mar Iglesias + Hossein Taghizadeh + surgeon
- Optimizing the Patient Pathway in CCA: From Diagnosis to Treatment Angela Lamarca Diogo Bugano
- Navigating Real-World Evidence in mIDH1 CCA with ProvIDHe
   Teresa Macarulla Yannick Buccella
- Evolving Therapeutic Landscape in advanced CCA
   Pascal Hammel Davide Melisi